O'Day Daniel Patrick: insider trades.
O'Day Daniel Patrick reported 10 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($6.1M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 8
- Companies
- 1
- Name as filed
- O'Day Daniel Patrick
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Gilead Sciences, Inc. (GILD) | Director, Officer · Chairman & CEO | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-10 | Gilead Sciences, Inc. | F | 4,230 | $144.81 | 581,683 | Form 4 |
| 2026-09-10 | Gilead Sciences, Inc. | M | 8,780 | — | 585,913 | Form 4 |
| 2026-09-01 | Gilead Sciences, Inc. | S | 1,600 | $147.51 | 590,533 | Form 4 |
| 2026-09-01 | Gilead Sciences, Inc. | S | 7,992 | $148.36 | 582,541 | Form 4 |
| 2026-09-01 | Gilead Sciences, Inc. | S | 5,408 | $149.38 | 577,133 | Form 4 |
| 2026-08-03 | Gilead Sciences, Inc. | S | 6,700 | $129.66 | 600,433 | Form 4 |
| 2026-08-03 | Gilead Sciences, Inc. | S | 600 | $131.34 | 592,133 | Form 4 |
| 2026-08-03 | Gilead Sciences, Inc. | S | 7,700 | $130.8 | 592,733 | Form 4 |
| 2026-07-01 | Gilead Sciences, Inc. | S | 11,900 | $126.09 | 610,233 | Form 4 |
| 2026-07-01 | Gilead Sciences, Inc. | S | 3,100 | $127.08 | 607,133 | Form 4 |
Questions
What stock did O'Day Daniel Patrick buy or sell?
O'Day Daniel Patrick reported 10 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($6.1M), across 1 company.
Is O'Day Daniel Patrick the same person as other filers with this name?
This page covers SEC CIK 1638643 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/o-day-daniel-patrick-1638643.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.